Bevacizumab for the treatment of high-grade glioma: an update after Phase III trials

Bibliography

• Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008;359(5):492-507
   PubMed Web of Science ®Google Scholar
• Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114(2):97-109
   PubMed Web of Science ®Google Scholar
• Khasraw M, Lassman AB. Advances in the treatment of malignant gliomas. Curr Oncol Rep 2010;12(1):26-33
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10(5):459-66
   PubMed Web of Science ®Google Scholar
• Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343(19):1350-4
   PubMed Web of Science ®Google Scholar
• Onishi M, Ichikawa T, Kurozumi K, Date I. Angiogenesis and invasion in glioma. Brain Tumor Pathol 2011;28(1):13-24
   PubMed Web of Science ®Google Scholar
• Kaur B, Khwaja FW, Severson EA, et al. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol 2005;7(2):134-53
   PubMed Web of Science ®Google Scholar
• Salmaggi A, Eoli M, Frigerio S, et al. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol 2003;62(3):297-303
   PubMed Web of Science ®Google Scholar
• Nam DH, Park K, Park C, et al. Intracranial inhibition of glioma cell growth by cyclooxygenase-2 inhibitor celecoxib. Oncol Rep 2004;11(2):263-8
   PubMed Web of Science ®Google Scholar
• Nabors LB FK, Mikkelsen T, Grujicic D, et al. A randomized phase II study investigating cilengitide added to standard chemoradiotherapy in patients with newly diagnosed glioblastoma with unmethylated O 6 -methylguanine-DNA methyltransferase (MGMT) gene promoter: initial report of the CORE study. 18th Annual SNO Scientific Meeting; San Francisco; 2013
   Google Scholar
• Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 2013;31(26):3212-18
   PubMed Web of Science ®Google Scholar
• de Groot JF, Lamborn KR, Chang SM, et al. Phase II study of aflibercept in recurrent malignant glioma: a north american brain tumor consortium study. J Clin Oncol 2011;29(19):2689-95
   PubMed Web of Science ®Google Scholar
• Stark-Vance VB. CPT-11 in the treatment of relapsed malignant glioma. Neuro Oncol 2005;7(3):369
   Web of Science ®Google Scholar
• Cokgor I, Friedman HS, Friedman AH. Chemotherapy for adults with malignant glioma. Cancer Invest 1999;17(4):264-72
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Filka E, Kuhn J, et al. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer 2003;97(9 Suppl):2381-6
   PubMed Web of Science ®Google Scholar
• Friedman HS, Petros WP, Friedman AH, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 1999;17(5):1516-25
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE II, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25(30):4722-9
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE II, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13(4):1253-9
   PubMed Web of Science ®Google Scholar
• Macdonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8(7):1277-80
   PubMed Web of Science ®Google Scholar
• Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27(5):740-5
   PubMed Web of Science ®Google Scholar
• Levin VA, Crafts DC, Norman DM, et al. Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. J Neurosurg 1977;47(3):329-35
   PubMed Web of Science ®Google Scholar
• Lu JF, Bruno R, Eppler S, et al. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 2008;62(5):779-86
   PubMed Web of Science ®Google Scholar
• Verheul HMW, Lolkema MPJ, Qian DZ, et al. Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res 2007;13(18):5341-7
   PubMed Web of Science ®Google Scholar
• Raizer JJ, Grimm S, Chamberlain MC, et al. A phase 2 trial of single‚ äêagent bevacizumab given in an every 3 week schedule for patients with recurrent high grade gliomas. Cancer 2010;116(22):5297-305
   PubMed Web of Science ®Google Scholar
• Taal W, Oosterkamp HM, Walenkamp AME, et al. A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: the Dutch BELOB study. ASCO Meeting Abstracts 2013;31(Suppl 15):2001
   Google Scholar
• Lai A, Tran A, Nghiemphu PL, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2011;29(2):142-8
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Reardon DA, et al. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res 2011;17(12):4119-24
   PubMed Web of Science ®Google Scholar
• Chinot O, Wick W, Mason W, et al. Phase III trial of bevacizumab added to standard radiotherapy and temozolomide for newly-diagnosed glioblastoma: mature progression-free survival and preliminary overall survival results in AVAGLIO. Neuro Oncol 2012;14(Suppl 6):vi101-vi05
   Google Scholar
• Chinot OL, Macdonald DR, Abrey LE, et al. Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. Curr Neurol Neurosci Rep 2013;13(5):347
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Dignam J, Won M, et al. RTOG 0825: phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). ASCO Meeting Abstracts 2013;31(Suppl 15):1
   Google Scholar
• Sulman EP, Won M, Blumenthal DT, et al. Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM). ASCO Meeting Abstracts 2013;31(Suppl 18):LBA2010
   Google Scholar
• Herrlinger U, Schaefer N, Steinbach JP, et al. Bevacizumab, irinotecan, and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT-non-methylated glioblastoma patients: first results from the randomized multicenter GLARIUS trial. ASCO Meeting Abstracts 2013;31(Suppl 15):LBA2000
   Google Scholar
• van den Bent MJ, Vogelbaum MA, Wen PY, et al. End point assessment in gliomas: novel treatments limit usefulness of classical macdonald's criteria. J Clin Oncol 2009;27(18):2905-8
   PubMed Web of Science ®Google Scholar
• Bokstein F, Shpigel S, Blumenthal DT. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 2008;112(10):2267-73
   PubMed Web of Science ®Google Scholar
• Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28(11):1963-72
   PubMed Web of Science ®Google Scholar
• de Groot JF, Fuller G, Kumar AJ, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 2010;12(3):233-42
   PubMed Web of Science ®Google Scholar
• Brandsma D, Van Den Bent MJ. Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol 2009;22(6):633
   PubMed Web of Science ®Google Scholar
• Taal W, Brandsma D, de Bruin HG, et al. Incidence of early pseudo‚ äêprogression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-10
   PubMed Web of Science ®Google Scholar
• Prados M, Cloughesy T, Samant M, et al. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol 2011;13(1):143-51
   PubMed Web of Science ®Google Scholar
• Scaringi C, Enrici RM, Minniti G. Combining molecular targeted agents with radiation therapy for malignant gliomas. Onco Targets Ther 2013;6:1079-95
   PubMed Web of Science ®Google Scholar
• Hoang T, Huang S, Armstrong E, et al. Enhancement of radiation response with bevacizumab. J Exp Clin Cancer Res 2012;31:37
   PubMedGoogle Scholar
• Lubelski D, Abdullah KG, Weil RJ, Marko NF. Bevacizumab for radiation necrosis following treatment of high grade glioma: a systematic review of the literature. J Neurooncol 2013;115(3):317-22
   PubMed Web of Science ®Google Scholar
• Omuro A, Beal K, Correa D, et al. Phase II study of bevacizumab, temozolomide and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma. Neuro Oncol 2011;13:59-60
   Web of Science ®Google Scholar
• Gutin PH, Iwamoto FM, Beal K, et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2009;75(1):156-63
   PubMed Web of Science ®Google Scholar
• Reardon DA, Desjardins A, Peters KB, et al. Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer 2011;117(23):5351-8
   PubMed Web of Science ®Google Scholar
• Reardon DA, Desjardins A, Peters KB, et al. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. J Neurooncol 2012;107(1):155-64
   PubMed Web of Science ®Google Scholar
• Reardon D, Desjardins A, Vredenburgh J, et al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer 2009;101(12):1986-94
   PubMed Web of Science ®Google Scholar
• Sathornsumetee S, Desjardins A, Vredenburgh JJ, et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol 2010;12(12):1300
   PubMed Web of Science ®Google Scholar
• Maron R, Vredenburgh J, Desjardins A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM). J Clin Oncol (Meeting Abstracts) 2008;26(Suppl 15):2074
   Google Scholar
• Badruddoja M, Pazzi M, Stea B, et al. Phase II study of biweekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma multiforme. J Clin Oncol (Meeting Abstracts) 2010;28(Suppl 15):e12554
   Google Scholar
• Levin VA, Bidaut L, Hou P, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 2011;79(5):1487-95
   PubMed Web of Science ®Google Scholar
• Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15(3):220-31
   PubMed Web of Science ®Google Scholar
• Piao Y, Liang J, Holmes L, et al. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro Oncol 2012;14(11):1379-92
   PubMed Web of Science ®Google Scholar
• Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 2009;15(14):4589-99
   PubMed Web of Science ®Google Scholar
• Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro Oncol 2013;15(2):242-50
   PubMed Web of Science ®Google Scholar
• Iwamoto FM, Abrey LE, Beal K, et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009;73(15):1200-6
   PubMed Web of Science ®Google Scholar
• Quant EC, Norden AD, Drappatz J, et al. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol 2009;11(5):550-5
   PubMed Web of Science ®Google Scholar
• Armstrong TS, Wen PY, Gilbert MR, Schiff D. Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors. Neuro Oncol 2012;14(10):1203-14
   PubMed Web of Science ®Google Scholar
• Khasraw M, Holodny A, Goldlust SA, DeAngelis LM. Intracranial hemorrhage in patients with cancer treated with bevacizumab: the memorial sloan-kettering experience. Ann Oncol 2012;23(2):458-63
   PubMed Web of Science ®Google Scholar
• Norden A, Bartolomeo J, Tanaka S, et al. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. J Neurooncol 2012;106(1):121-5
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27(28):4733-40
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study. ASCO Meeting Abstracts 2013;31(Suppl 18):LBA2009
   Google Scholar
• Wang R, Chadalavada K, Wilshire J, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010;468(7325):829-33
   PubMed Web of Science ®Google Scholar
• Ahluwalia MS, Patel M, Peereboom DM. Role of tyrosine kinase inhibitors in the management of high-grade gliomas. Expert Rev Anticancer Ther 2011;11(11):1739-48
   PubMed Web of Science ®Google Scholar
• Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57(20):4593-9
   PubMed Web of Science ®Google Scholar
• Desjardins A, Reardon DA, Herndon JE II, et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 2008;14(21):7068-73
   PubMed Web of Science ®Google Scholar
• Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008;70(10):779-87
   PubMed Web of Science ®Google Scholar
• Narayana A, Kelly P, Golfinos J, et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg 2009;110(1):173-80
   PubMed Web of Science ®Google Scholar
• Nghiemphu PL, Liu W, Lee Y, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 2009;72(14):1217-22
   PubMed Web of Science ®Google Scholar
• Poulsen HS, Grunnet K, Sorensen M, et al. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol (Madr) 2009;48(1):52-8
   PubMed Web of Science ®Google Scholar
• Zuniga RM, Torcuator R, Jain R, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 2009;91(3):329-36
   PubMed Web of Science ®Google Scholar
• Taillibert S, Vincent LA, Granger B, et al. Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology 2009;72(18):1601-6
   PubMed Web of Science ®Google Scholar
• Hofer S, Elandt K, Greil R, et al. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta oncologica (Stockholm, Sweden) 2011;50(5):630-5
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Johnston S. Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer 2009;115(8):1734-43
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Johnston S. Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. J Neurooncol 2009;91(3):359-67
   PubMed Web of Science ®Google Scholar
• Gruber M, Raza S, Gruber D, Narayana A. Bevacizumab in combination with radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma: update progression-free survival, overall survival, and toxicity. J Clin Oncol (Meeting Abstracts) 2009;27(15S):2017
   Google Scholar
• Omuro A, Beal K, Karimi S, et al. Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM). J Clin Oncol (Meeting Abstracts) 2011;29(15 Suppl):2028
   Google Scholar
• Shih K, Spigel D, Burris H III, et al. Phase II trial of radiation therapy/temozolomide/bevacizumab followed by bevacizumab/everolimus in the first-line treatment of glioblastoma multiforme (GBM). J Clin Oncol (Meeting Abstracts) 2010;28(15 Suppl):2075
   Google Scholar
• Vredenburgh JJ, Desjardins A, Kirkpatrick JP, et al. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2012;82(1):58-66
   PubMed Web of Science ®Google Scholar